The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcome of patients (PTS) with advanced epithelioid hemangioendothelioma (EHE) after failure on sirolimus (S).
 
Claudia Giani
No Relationships to Disclose
 
Rosalba Miceli
No Relationships to Disclose
 
Giacomo Giulio Baldi
Honoraria - Eisai; GlaxoSmithKline; Lilly; MSD; PharmaMar
Consulting or Advisory Role - Aboutevents Srl; Boehringer Ingelheim; Eisai; Lilly; MSD; PharmaMar
Travel, Accommodations, Expenses - Lilly; Novartis; PharmaMar
 
Antonella Brunello
Consulting or Advisory Role - GlaxoSmithKline; PharmaMar
Travel, Accommodations, Expenses - PharmaMar
 
Bruno Vincenzi
Consulting or Advisory Role - abbott; GlaxoSmithKline; Lilly
Speakers' Bureau - PharmaMar
Research Funding - BD Bard
 
Carlo Morosi
No Relationships to Disclose
 
Francesca Gabriella Greco
No Relationships to Disclose
 
Alessandro Gronchi
Honoraria - Deciphera; Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Lilly; Nanobiotix; Novartis; Pfizer; PharmaMar; SpringWorks Therapeutics
Research Funding - Nanobiotix (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Nanobiotix; PharmaMar
 
Matilde Ingrosso
Research Funding - Advenchen Laboratories (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); Foghorn Therapeutics (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Oncology (Inst); SpringWorks Therapeutics (Inst)
 
Anna Maria Frezza
No Relationships to Disclose
 
Paolo Giovanni Casali
Research Funding - Advenchen Laboratories (Inst); Amgen/Dompé (Inst); Arog (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Daiihi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Therapeutics (Inst)
 
Silva Ljevar
No Relationships to Disclose
 
Silvia Stacchiotti
Honoraria - Aadi; Boehringer Ingelheim; Gentili; GlaxoSmithKline; PharmaMar
Consulting or Advisory Role - Agenus; Astex Pharmaceuticals; Bavarian Nordic; Bayer; Boehringer Ingelheim; Daiichi Sankyo; GlaxoSmithKline; Ikena Oncology; MaxiVax; Novartis; PharmaMar; Rain Therapeutics; Regeneron; SERVIER
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar